ZAI LAB LTD. news, videos and press releases
For more news please use our advanced search feature.
ZAI LAB LTD. - More news...
ZAI LAB LTD. - More news...
- Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in November Investor Conferences
- Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
- Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
- Zai Lab Announces Participation in September Investor Conferences
- Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
- Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
- INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zai Lab Limited and Encourages Investors with Losses to Contact the Firm
- JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
- Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
- Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
- Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis
- Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
- Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
- Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
- Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
- Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
- Zai Lab Announces Participation in June Investor Conferences
- Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
- Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
- Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
- Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
- Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
- Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
- Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in March Investor Conferences
- Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
- Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
